

SPDR S&P Pharmaceuticals ETF (Thu, Jun 20, 2024)

Sell candidate since Jun 11, 2024 Loss -1.87%

StockInvest.us
Gyneju st. 14, "ROCKIT"
Vilnius, LT-01109
Lithuania



score: **-2.27**
#17160/ 50877

Trend: Sell
MV Long: Sell
MV Short: Sell
Pivot: Sell
Volume: Buy
MACD: Buy

Tech commentaries:

The **SPDR S&P Pharmaceuticals** ETF price gained **0.378%** on the last trading day (Thursday, 20th Jun 2024), rising from **\$39.72** to **\$39.87**. During the last trading day the ETF fluctuated **1.14%** from a day low at **\$39.45** to a day high of **\$39.90**. The price has fallen in 8 of the last 10 days and is down by **-2.23%** for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, **30 thousand** more shares were traded than the day before. In total, **68 thousand** shares were bought and sold for approximately **\$2.69 million**.

The ETF lies in the middle of a falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the ETF is expected to fall **-3.80%** during the next 3 months and, with a 90% probability hold a price between **\$36.65** and **\$39.22** at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume is rising along with the price. This is considered to be a good technical signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. The **SPDR S&P Pharmaceuticals** ETF holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at **\$40.10** and **\$40.61**. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on **Wednesday, May 15, 2024**, and so far it has fallen **-3.70%**. Further fall is indicated until a new bottom pivot has been found.

SPDR S&P Pharmaceuticals finds support from accumulated volume at **\$39.79** and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. On the upside the ETF meets some resistance just above today's level from accumulated volume at **\$40.15**, **\$42.31** and **\$43.13**.

In general the ETF tends to have very controlled movements and with good liquidity the risk is considered very low in this stock. During the last day, the ETF moved **\$0.450** between high and low, or **1.14%**. For the last week the ETF has had daily average volatility of **0.83%**.

SPDR S&P Pharmaceuticals holds several negative signals and is within a falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this ETF.

Risk: **Low**

Evaluation: **Sell Candidate**

Disclaimer: StockInvest.us is a research service that provides financial data and technical analysis of stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "StockInvest.us". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy.